In 2013, the American Medical Association officially voted to declare obesity a disease, which demands both treatment and prevention efforts
Originally developed as a treatment for muscular dystrophy, a study evaluating the safety of this MSTN inhibitor found no significant side effects, except for skin hypersensitivity reactions, such as rashes, particularly in cohorts receiving higher doses.[68] Landogrozumab (LY2495655) is another antibody that binds to and neutralizes MSTN
Additionally, the therapeutic potential of GLP-1RAs and other incretin-based NuSHs in reversing the drivers of hepatocarcinogenesis in MASLD may be grounded in their ability to restore hepatic insulin sensitivity and correct metabolic dysregulation
Here is how to think about them together
Redono C, Rocamora A, Villoria F, et al
But just because a drug is off the list doesnt mean supply is guaranteed